首页 > 最新文献

Reviews on recent clinical trials最新文献

英文 中文
Cerebral Vasospasm: Practical Review of Diagnosis and Management. 脑血管痉挛:诊断和治疗的实用回顾。
IF 1.9 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887117666220810121048
Tatsiana Romenskaya, Yaroslava Longhitano, Fabio Piccolella, Jack Marshall Berger, Marco Artico, Samanta Taurone, Antonio Maconi, Angela Saviano, Michela Caramuta, Gabriele Savioli, Christian Zanza
BACKGROUNDCerebral vasospasm is one of the frequent complications that can occur following subarachnoid hemorrhage (SAH). With new protocols in the management of SAH, the combined risk of death and long-term disability has been reduced by about 10% compared with the past.OBJECTIVEThis work aims to report the latest updates on the vasospasm developing after the SAH in patients in the ICU department. In this short review, we reviewed the latest scientific findings on the mechanisms of vasospasm, and, in addition, we considered it necessary to review the literature to report the tools for early diagnosis of vasospasm and the best treatment strategies to prevent the negative outcome in patients admitted to ICU.SCOPEThe aim of this narrative review is to report the main characteristics of vasospasm, new diagnostic methods and, especially, more effective treatment of vasospasm.MATERIALS AND METHODSThe peer-reviewed articles analyzed were selected from PubMed, google scholar, Embase, Scopus databases in the previous 20 years and using the keywords words "vasospam", "vasospasm diagnosis", "vasospasm and SAH", "vasospasm treatment", non-traumatic brain injury. Among the 78 papers identified, 43 articles were selected; after title - abstract examination and removing the duplicates, only 31 articles were examined.RESULTSVasospasm can be classified according to clinical (asymptomatic vs symptomatic) and diagnostic (angiographic vs ultrasound) methods. Various procedures such as TCD and CT perfusion are used for early diagnosis and close monitoring of this condition. The treatment of vasospasm consists of both prevention (nimodipine, statitis, magnesium sulphate) and active treatment (mainly endovascular).CONCLUSIONAs the review shows, vasospasm is a complication of SAH, a complication that is difficult to recognise early and treat with the best outcome. However, with the equipment we have, it has been possible to improve the outcome, even if it is still not ideal, of patients who develop vasospasm. Several studies are in the final stages to improve the outcome of this unfortunately frequent condition.
背景:脑血管痉挛是蛛网膜下腔出血(SAH)后常见的并发症之一。随着SAH管理的新方案,与过去相比,死亡和长期残疾的综合风险降低了约10%。目的:本工作旨在报道ICU患者SAH后血管痉挛的最新进展。在这篇简短的综述中,我们回顾了关于血管痉挛机制的最新科学发现,此外,我们认为有必要回顾文献,以报告血管痉挛的早期诊断工具和预防ICU患者不良结局的最佳治疗策略。目的:这篇叙述性综述的目的是报道血管痉挛的主要特征,新的诊断方法,特别是更有效的治疗血管痉挛。材料和方法:采用关键词“血管痉挛”、“血管痉挛诊断”、“血管痉挛和SAH”、“血管痉挛治疗”和非创伤性脑损伤,从PubMed、Google scholar、Embase和Scopus数据库中选取近20年发表的同行评议文章进行分析。在确定的78篇论文中,入选43篇;在标题-摘要审查和删除重复后,只有31篇文章被审查。结果:血管痉挛可根据临床(无症状vs有症状)和诊断(血管造影vs超声)方法进行分类。各种程序如TCD和CT灌注用于早期诊断和密切监测这种情况。血管痉挛的治疗包括预防(尼莫地平、消炎和硫酸镁)和积极治疗(主要是血管内治疗)。结论:综述显示,血管痉挛是SAH的并发症,是一种难以早期发现和治疗的并发症。然而,有了我们现有的设备,已经有可能改善血管痉挛患者的预后,即使它仍然不理想。一些研究正处于最后阶段,以改善这种不幸的常见疾病的结果。
{"title":"Cerebral Vasospasm: Practical Review of Diagnosis and Management.","authors":"Tatsiana Romenskaya, Yaroslava Longhitano, Fabio Piccolella, Jack Marshall Berger, Marco Artico, Samanta Taurone, Antonio Maconi, Angela Saviano, Michela Caramuta, Gabriele Savioli, Christian Zanza","doi":"10.2174/1574887117666220810121048","DOIUrl":"https://doi.org/10.2174/1574887117666220810121048","url":null,"abstract":"BACKGROUND\u0000Cerebral vasospasm is one of the frequent complications that can occur following subarachnoid hemorrhage (SAH). With new protocols in the management of SAH, the combined risk of death and long-term disability has been reduced by about 10% compared with the past.\u0000\u0000\u0000OBJECTIVE\u0000This work aims to report the latest updates on the vasospasm developing after the SAH in patients in the ICU department. In this short review, we reviewed the latest scientific findings on the mechanisms of vasospasm, and, in addition, we considered it necessary to review the literature to report the tools for early diagnosis of vasospasm and the best treatment strategies to prevent the negative outcome in patients admitted to ICU.\u0000\u0000\u0000SCOPE\u0000The aim of this narrative review is to report the main characteristics of vasospasm, new diagnostic methods and, especially, more effective treatment of vasospasm.\u0000\u0000\u0000MATERIALS AND METHODS\u0000The peer-reviewed articles analyzed were selected from PubMed, google scholar, Embase, Scopus databases in the previous 20 years and using the keywords words \"vasospam\", \"vasospasm diagnosis\", \"vasospasm and SAH\", \"vasospasm treatment\", non-traumatic brain injury. Among the 78 papers identified, 43 articles were selected; after title - abstract examination and removing the duplicates, only 31 articles were examined.\u0000\u0000\u0000RESULTS\u0000Vasospasm can be classified according to clinical (asymptomatic vs symptomatic) and diagnostic (angiographic vs ultrasound) methods. Various procedures such as TCD and CT perfusion are used for early diagnosis and close monitoring of this condition. The treatment of vasospasm consists of both prevention (nimodipine, statitis, magnesium sulphate) and active treatment (mainly endovascular).\u0000\u0000\u0000CONCLUSION\u0000As the review shows, vasospasm is a complication of SAH, a complication that is difficult to recognise early and treat with the best outcome. However, with the equipment we have, it has been possible to improve the outcome, even if it is still not ideal, of patients who develop vasospasm. Several studies are in the final stages to improve the outcome of this unfortunately frequent condition.","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":"18 1","pages":"12-18"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9259262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Role of the Clinical Data Managers During the COVID-19 Pandemic: An Overview. 临床数据管理人员在COVID-19大流行期间的作用:概述。
IF 1.9 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887118666221208123724
Rishitha Sajja

Background: The COVID-19 pandemic has significantly changed the implementation of clinical trials. A large focus has been directed on clinical trial design, timeline, and best practices. It has led clinical trial study teams to update the existing processes and perform a risk assessment to mitigate the impact of the COVID-19 pandemic according to ICH-GCP (Good Clinical Practice) requirements. Data management plays a crucial role in understanding the study team's needs and developing innovative solutions. The Clinical Data Manager (CDM) is a core clinical trial Study Team member, responsible for promptly collecting, managing, and delivering complete, highquality data.

Objective: The COVID-19 pandemic required the Clinical Data Manager (CDM) to respond to changing needs by adapting data collection tools, data review strategies, and data management processes to answer new questions and address new challenges. CDMs became responsible for identifying how the COVID-19 pandemic impacted current data management processes and documentation and implementing changes to reflect new ways of working. The present article reviews the impact of the COVID-19 pandemic on clinical trials and the solutions adopted by the Clinical Data manager.

Conclusion: The collection of COVID-19-related data points provides a better understanding of patient safety during the pandemic and proactively fulfills the growing regulatory interests. Strategies and innovative solutions adopted by the Clinical Data Manager serve as guidance for the clinical research team during the crisis to make the trials more robust and patient-centered.

背景:新冠肺炎大流行对临床试验的实施产生了重大影响。临床试验设计、时间安排和最佳实践是一个很大的焦点。世卫组织已领导临床试验研究小组更新现有流程,并根据ICH-GCP(良好临床规范)要求进行风险评估,以减轻COVID-19大流行的影响。数据管理在理解研究团队的需求和开发创新解决方案方面起着至关重要的作用。临床数据经理(CDM)是临床试验研究团队的核心成员,负责及时收集、管理和提供完整、高质量的数据。目的:COVID-19大流行要求临床数据管理人员(CDM)通过调整数据收集工具、数据审查策略和数据管理流程来应对不断变化的需求,以回答新问题和应对新挑战。清洁发展机制负责确定COVID-19大流行如何影响当前的数据管理流程和文件,并实施变更以反映新的工作方式。本文综述了COVID-19大流行对临床试验的影响以及临床数据管理人员采取的解决方案。结论:covid -19相关数据点的收集有助于更好地了解大流行期间的患者安全,并主动满足日益增长的监管利益。临床数据经理采用的策略和创新解决方案在危机期间为临床研究团队提供指导,使试验更加稳健,以患者为中心。
{"title":"Role of the Clinical Data Managers During the COVID-19 Pandemic: An Overview.","authors":"Rishitha Sajja","doi":"10.2174/1574887118666221208123724","DOIUrl":"https://doi.org/10.2174/1574887118666221208123724","url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic has significantly changed the implementation of clinical trials. A large focus has been directed on clinical trial design, timeline, and best practices. It has led clinical trial study teams to update the existing processes and perform a risk assessment to mitigate the impact of the COVID-19 pandemic according to ICH-GCP (Good Clinical Practice) requirements. Data management plays a crucial role in understanding the study team's needs and developing innovative solutions. The Clinical Data Manager (CDM) is a core clinical trial Study Team member, responsible for promptly collecting, managing, and delivering complete, highquality data.</p><p><strong>Objective: </strong>The COVID-19 pandemic required the Clinical Data Manager (CDM) to respond to changing needs by adapting data collection tools, data review strategies, and data management processes to answer new questions and address new challenges. CDMs became responsible for identifying how the COVID-19 pandemic impacted current data management processes and documentation and implementing changes to reflect new ways of working. The present article reviews the impact of the COVID-19 pandemic on clinical trials and the solutions adopted by the Clinical Data manager.</p><p><strong>Conclusion: </strong>The collection of COVID-19-related data points provides a better understanding of patient safety during the pandemic and proactively fulfills the growing regulatory interests. Strategies and innovative solutions adopted by the Clinical Data Manager serve as guidance for the clinical research team during the crisis to make the trials more robust and patient-centered.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":"18 1","pages":"41-45"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9266180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer. 病人服用恩杂鲁胺真的失败了吗?恩杂鲁胺耐药少进展性转移性去势耐药前列腺癌一例报告及需要考虑的问题。
IF 1.9 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887118666230412112136
Georgios I Papageorgiou, Nikolaos Skouteris, Aikaterini Kosma, Athina Markouizou, Nikolaos Charalampakis

Background: Metastatic castrate-resistant prostate cancer (mCRPC) is a challenging disease, especially in heavily pretreated patients. Androgen pathway inhibitors have contributed to a notable improvement in the overall survival and quality of life in patients with mCRPC during the last decade. Still, a considerable percentage of patients are unable to draw benefits from this drug category and are deprived of a treatment that offers limited toxicity and preserves a good quality of life. The mechanisms leading to this pre-existing or acquired resistance, as well as the possible strategies to overcome this resistance have been put at the center of scientists' attention.

Case presentation: With the present report we present the case of a 70-year-old patient with mCRPC, who was apparently an enzalutamide non-responder, but a multimodal approach with enzalutamide continuation and irradiation to his symptomatic oligoprogressive disease converted him to a responder with clinical, biochemical and imaging response; furthermore, we discuss the existing data providing evidence for the use of metastasis-directed therapy in combination with androgen pathway inhibitors in order to overcome drug resistance in patients with oligoprogressive disease.

Conclusion: A considerable proportion of patients with oligometastatic or oligoprogressive prostate cancer who seem not to respond to androgen pathway inhibitors, such as enzalutamide, due to preexisting or acquired resistance, could benefit from MDT with a multimodal treatment approach. This strategy allows androgen pathway inhibitor continuation beyond biochemical progression and delays the switch to next-line systemic treatment.

背景:转移性去势抵抗性前列腺癌(mCRPC)是一种具有挑战性的疾病,特别是在大量预处理的患者中。在过去的十年中,雄激素途径抑制剂对mCRPC患者的总体生存率和生活质量的显著改善做出了贡献。尽管如此,仍有相当大比例的患者无法从这类药物中获益,无法获得毒性有限且能保持良好生活质量的治疗。导致这种预先存在或获得性耐药性的机制,以及克服这种耐药性的可能策略,一直是科学家关注的焦点。病例介绍:在本报告中,我们报告了一名70岁的mCRPC患者,他显然对恩杂鲁胺无反应,但对他的症状性少进展性疾病进行了多模式治疗,继续使用恩杂鲁胺并进行放射治疗,使他对临床、生化和影像学有反应;此外,我们讨论了现有的数据,这些数据为使用转移导向治疗联合雄激素途径抑制剂来克服少进展性疾病患者的耐药性提供了证据。结论:相当比例的少转移性或少进展性前列腺癌患者,由于先前存在或获得性耐药,对雄激素途径抑制剂(如enzalutamide)似乎没有反应,可以从MDT和多模式治疗方法中获益。这种策略允许雄激素途径抑制剂在生化进展之外继续存在,并延迟转向下一步全身治疗。
{"title":"Is the Patient Actually Failing on Enzalutamide? A Case Report and Issues to Consider in Enzalutamide-Resistant Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer.","authors":"Georgios I Papageorgiou,&nbsp;Nikolaos Skouteris,&nbsp;Aikaterini Kosma,&nbsp;Athina Markouizou,&nbsp;Nikolaos Charalampakis","doi":"10.2174/1574887118666230412112136","DOIUrl":"https://doi.org/10.2174/1574887118666230412112136","url":null,"abstract":"<p><strong>Background: </strong>Metastatic castrate-resistant prostate cancer (mCRPC) is a challenging disease, especially in heavily pretreated patients. Androgen pathway inhibitors have contributed to a notable improvement in the overall survival and quality of life in patients with mCRPC during the last decade. Still, a considerable percentage of patients are unable to draw benefits from this drug category and are deprived of a treatment that offers limited toxicity and preserves a good quality of life. The mechanisms leading to this pre-existing or acquired resistance, as well as the possible strategies to overcome this resistance have been put at the center of scientists' attention.</p><p><strong>Case presentation: </strong>With the present report we present the case of a 70-year-old patient with mCRPC, who was apparently an enzalutamide non-responder, but a multimodal approach with enzalutamide continuation and irradiation to his symptomatic oligoprogressive disease converted him to a responder with clinical, biochemical and imaging response; furthermore, we discuss the existing data providing evidence for the use of metastasis-directed therapy in combination with androgen pathway inhibitors in order to overcome drug resistance in patients with oligoprogressive disease.</p><p><strong>Conclusion: </strong>A considerable proportion of patients with oligometastatic or oligoprogressive prostate cancer who seem not to respond to androgen pathway inhibitors, such as enzalutamide, due to preexisting or acquired resistance, could benefit from MDT with a multimodal treatment approach. This strategy allows androgen pathway inhibitor continuation beyond biochemical progression and delays the switch to next-line systemic treatment.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":"18 2","pages":"146-155"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9562894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
N-Acetyl Cysteine as an Add-on Therapy is Useful in Treating Acute Lumbar Radiculopathy Caused by Disc Herniation: Results of a Randomized, Controlled Clinical Trial. N-乙酰半胱氨酸作为一种附加疗法可用于治疗椎间盘突出症引起的急性腰根病变:一项随机对照临床试验的结果。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/0115748871250545230919055109
Bijan Heidari, Zeinab-Alsadat Seyedian, Maryam Mehrpooya, Davoud Ahmadimoghaddam, Mahtabalsadat Mirjalili, Masood Ghiasian

Background: Available experimental and clinical evidence indicates that N-Acetyl cysteine (NAC) may have an analgesic role in specific pain conditions, particularly neuropathic pain. Thus, we hypothesized that NAC supplementation might be also helpful in decreasing pain and improving pain-related disability in patients with acute radiculopathy. We designed this study to investigate the potential use of NAC-adjunctive treatment to Nonsteroidal Anti- Inflammatory Drugs (NSAIDs) in patients with acute radiculopathy secondary to lumbar intervertebral disc herniation.

Methods: Sixty-two patients diagnosed with acute lumbar radiculopathy associated with disc herniation were randomly allocated to the NAC or the placebo groups. Besides naproxen at a dose of 500 mg twice a day, participants based on their allocation group started with NAC or matched placebo at a dose of 600 mg twice a day for eight weeks. The pain severity, measured by the Visual Analog Scale (VAS), and pain-related disability measured by the Oswestry Disability Index (ODI) were measured at baseline and weeks 2, 4, and 8 of treatment. Global improvement of symptoms rated by Patient and Clinical Global Impressions of Change (PGIC and CGIC) was also recorded at the end of week 8. All analyses were conducted on an Intentionto- Treat (ITT) analysis data set.

Results: A comparison of the VAS and ODI scores at weeks 2 and 4 of the treatment between the two groups did not show a significant difference. In contrast, from week 4 to week 8, we noticed a significantly greater reduction in the mean VAS and ODI scores in the NAC group compared to the placebo group (p-value <0.001 for both variables). In parallel with these results, also, more NAC-treated than placebo-treated patients achieved treatment success defined as ''very much'' or ''much improved'' on CGIC and PGIC scales, and these differences reached a significant level (p-value = .011 and p-value = .043).

Conclusions: This study suggested that NAC might be a relevant candidate for adjunct therapy in managing acute lumbar radiculopathy. Additional clinical trials are needed to validate these findings.

背景:现有的实验和临床证据表明,N-乙酰半胱氨酸(NAC)可能在特定的疼痛条件下,特别是神经性疼痛中发挥镇痛作用。因此,我们假设补充NAC也可能有助于减轻急性神经根病患者的疼痛和改善与疼痛相关的残疾。本研究旨在探讨NAC辅助治疗非甾体抗炎药(NSAIDs)在腰椎间盘突出症继发急性神经根病患者中的潜在用途。方法:将62例诊断为急性腰神经根病伴椎间盘突出症的患者随机分为NAC组或安慰剂组。除了每天两次500 mg的萘普生剂量外,基于分配组的参与者开始服用NAC或匹配的安慰剂,每天两次600 mg,持续八周。在基线和治疗的第2、4和8周,通过视觉模拟量表(VAS)测量疼痛严重程度,并通过奥斯韦斯特里残疾指数(ODI)测量疼痛相关残疾。在第8周结束时,还记录了患者和临床整体变化印象(PGIC和CGIC)评定的症状的整体改善。所有分析均在意向治疗(ITT)分析数据集上进行。结果:两组在治疗第2周和第4周的VAS和ODI评分比较没有显示出显著差异。而从第4周到第8周,我们注意到,与安慰剂组相比,NAC组的平均VAS和ODI评分显著降低(p值结论:这项研究表明,NAC可能是治疗急性腰神经根病的辅助治疗的相关候选者。还需要更多的临床试验来验证这些发现。试验注册:该试验在Clinicaltrials.gov上注册(识别码:IRCT2012021 5009014N381)。注册日期:2021-02-06。
{"title":"N-Acetyl Cysteine as an Add-on Therapy is Useful in Treating Acute Lumbar Radiculopathy Caused by Disc Herniation: Results of a Randomized, Controlled Clinical Trial.","authors":"Bijan Heidari, Zeinab-Alsadat Seyedian, Maryam Mehrpooya, Davoud Ahmadimoghaddam, Mahtabalsadat Mirjalili, Masood Ghiasian","doi":"10.2174/0115748871250545230919055109","DOIUrl":"10.2174/0115748871250545230919055109","url":null,"abstract":"<p><strong>Background: </strong>Available experimental and clinical evidence indicates that N-Acetyl cysteine (NAC) may have an analgesic role in specific pain conditions, particularly neuropathic pain. Thus, we hypothesized that NAC supplementation might be also helpful in decreasing pain and improving pain-related disability in patients with acute radiculopathy. We designed this study to investigate the potential use of NAC-adjunctive treatment to Nonsteroidal Anti- Inflammatory Drugs (NSAIDs) in patients with acute radiculopathy secondary to lumbar intervertebral disc herniation.</p><p><strong>Methods: </strong>Sixty-two patients diagnosed with acute lumbar radiculopathy associated with disc herniation were randomly allocated to the NAC or the placebo groups. Besides naproxen at a dose of 500 mg twice a day, participants based on their allocation group started with NAC or matched placebo at a dose of 600 mg twice a day for eight weeks. The pain severity, measured by the Visual Analog Scale (VAS), and pain-related disability measured by the Oswestry Disability Index (ODI) were measured at baseline and weeks 2, 4, and 8 of treatment. Global improvement of symptoms rated by Patient and Clinical Global Impressions of Change (PGIC and CGIC) was also recorded at the end of week 8. All analyses were conducted on an Intentionto- Treat (ITT) analysis data set.</p><p><strong>Results: </strong>A comparison of the VAS and ODI scores at weeks 2 and 4 of the treatment between the two groups did not show a significant difference. In contrast, from week 4 to week 8, we noticed a significantly greater reduction in the mean VAS and ODI scores in the NAC group compared to the placebo group (p-value <0.001 for both variables). In parallel with these results, also, more NAC-treated than placebo-treated patients achieved treatment success defined as ''very much'' or ''much improved'' on CGIC and PGIC scales, and these differences reached a significant level (p-value = .011 and p-value = .043).</p><p><strong>Conclusions: </strong>This study suggested that NAC might be a relevant candidate for adjunct therapy in managing acute lumbar radiculopathy. Additional clinical trials are needed to validate these findings.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"288-299"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41157686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lower Gastrointestinal Bleeding in the Emergency Department: High- Volume vs. Low-Volume Peg Bowel Preparation for Colonoscopy: A Randomized Trial. 急诊科下消化道出血:大容量与小容量结肠镜准备:一项随机试验。
IF 1.9 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887117666220908152754
Angela Saviano, Carmine Petruzziello, Maria Elena Riccioni, Marcello Di Pumpo, Martina Petrucci, Mattia Brigida, Christian Zanza, Marcello Candelli, Francesco Franceschi, Veronica Ojetti

Background: Lower Gastrointestinal Bleeding (LGIB) is a common cause of admission to the Emergency Department (ED). Early colonoscopy is the exam of choice for evaluating LGIB, and an adequate colon cleansing is essential. High-volume solution 4L-PEG is largely used, but it has some limitations. Low-volume solution 2L-PEG may improve patient's tolerability and compliance, reducing the time of administration and speeding up the exam.

Patients and methods: We conducted a randomized 1:1, prospective observational monocentric study in 228 patients (144M/84F) with LGIB. 121 (69M/52F) received the High-Volume, while 107 (75M/32F) received Low-Volume. They completed a "satisfaction questionnaire" (taste and smell, mood, time of taking, general experience). We collected the results of the Boston Bowel Preparation Scale (BBPS) and the final diagnosis. The study was retrospectively registered on clinicaltrial.gov with protocol number NCT0536 2227.

Results: A mean value of BBPS 6,3 was achieved by both groups (p=0.57). Regarding smell, taste, mood and time of taking (1 to 5), we do not find any statistically differences. The overall satisfaction between the two preparations was 2.90 for low-volume compared to 3.17 for Highvolume (p=0.06). No side effects were reported. The proportion of patients without an evident source of bleeding was higher in High volume preparations compared to Low-volume (39% vs. 30%, respectively).

Conclusion: Low volume bowel preparation showed the same efficacy and tolerability with better satisfaction compared with high volume. Low-volume could represent an effective and more desirable preparation for patients in the ED.

背景:下消化道出血(LGIB)是急诊科(ED)入院的常见原因。早期结肠镜检查是评估LGIB的首选检查,充分的结肠清洗是必不可少的。大容量溶液4L-PEG被广泛使用,但它有一些局限性。小体积2L-PEG溶液可以提高患者的耐受性和依从性,减少给药时间,加快检查速度。患者和方法:我们对228例LGIB患者(144M/84F)进行了一项随机1:1、前瞻性单中心观察研究。121 (69M/52F)接收高容量,而107 (75M/32F)接收低容量。他们完成了一份“满意度问卷”(味觉和嗅觉、情绪、服药时间、总体体验)。我们收集了波士顿肠道准备量表(BBPS)的结果和最终诊断。该研究在clinicaltrial.gov上回顾性注册,协议号为NCT0536 2227。结果:两组BBPS平均为6,3 (p=0.57)。在嗅觉、味觉、情绪和服药时间(1 ~ 5)方面,我们没有发现统计学上的差异。两种制剂的总体满意度在小容量组为2.90,而高容量组为3.17 (p=0.06)。没有副作用的报道。大容量制剂中无明显出血源的患者比例高于小容量制剂(分别为39%和30%)。结论:与大容量肠道准备相比,小容量肠道准备具有相同的疗效和耐受性,且满意度更高。对于急诊科的病人来说,小容量的准备是一种有效的、更理想的准备。
{"title":"Lower Gastrointestinal Bleeding in the Emergency Department: High- Volume vs. Low-Volume Peg Bowel Preparation for Colonoscopy: A Randomized Trial.","authors":"Angela Saviano,&nbsp;Carmine Petruzziello,&nbsp;Maria Elena Riccioni,&nbsp;Marcello Di Pumpo,&nbsp;Martina Petrucci,&nbsp;Mattia Brigida,&nbsp;Christian Zanza,&nbsp;Marcello Candelli,&nbsp;Francesco Franceschi,&nbsp;Veronica Ojetti","doi":"10.2174/1574887117666220908152754","DOIUrl":"https://doi.org/10.2174/1574887117666220908152754","url":null,"abstract":"<p><strong>Background: </strong>Lower Gastrointestinal Bleeding (LGIB) is a common cause of admission to the Emergency Department (ED). Early colonoscopy is the exam of choice for evaluating LGIB, and an adequate colon cleansing is essential. High-volume solution 4L-PEG is largely used, but it has some limitations. Low-volume solution 2L-PEG may improve patient's tolerability and compliance, reducing the time of administration and speeding up the exam.</p><p><strong>Patients and methods: </strong>We conducted a randomized 1:1, prospective observational monocentric study in 228 patients (144M/84F) with LGIB. 121 (69M/52F) received the High-Volume, while 107 (75M/32F) received Low-Volume. They completed a \"satisfaction questionnaire\" (taste and smell, mood, time of taking, general experience). We collected the results of the Boston Bowel Preparation Scale (BBPS) and the final diagnosis. The study was retrospectively registered on clinicaltrial.gov with protocol number NCT0536 2227.</p><p><strong>Results: </strong>A mean value of BBPS 6,3 was achieved by both groups (p=0.57). Regarding smell, taste, mood and time of taking (1 to 5), we do not find any statistically differences. The overall satisfaction between the two preparations was 2.90 for low-volume compared to 3.17 for Highvolume (p=0.06). No side effects were reported. The proportion of patients without an evident source of bleeding was higher in High volume preparations compared to Low-volume (39% vs. 30%, respectively).</p><p><strong>Conclusion: </strong>Low volume bowel preparation showed the same efficacy and tolerability with better satisfaction compared with high volume. Low-volume could represent an effective and more desirable preparation for patients in the ED.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":"18 1","pages":"76-81"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9259280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of Telenursing on the Quality of Life of Caregivers of Older Patients with Stroke. 远程护理对老年中风患者护理人员生活质量的影响
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887118666230522163725
Fatemeh Mohammadi, Hoda Bani Ardalan, Leila Dehghankar, Seyedeh Ameneh Motalebi

Background: Family caregivers of stroke patients suffer from a high caregiving burden that affects their quality of life. Telenursing can provide caregivers and patients with services at the lowest cost and full access. Therefore, the aim of this study was to investigate the impact of telenursing on the quality of life of caregivers of older stroke patients.

Methods: A total of 79 family caregivers of older stroke patients participated in this randomized clinical trial. The samples were selected from caregivers of older stroke patients admitted to a teaching hospital in Qazvin, Iran. They were randomly divided into two groups. The intervention group participated in an educational intervention for 12 weeks through telephone follow-up and social media. The Barthel Scale and the 36-item Short Form Survey (SF-36) were used for data collection. The chi-square and independent and paired t-tests were used to analyze the data.

Results: The mean age of 79 caregivers participating in the study was 46.16 ± 11.32 years. No significant differences were found between the two groups at baseline. However, the independent ttest showed significant differences in the psychological subscale (p <0.001) between the intervention and control groups after the intervention. In addition, the results of the paired t-test showed significant improvements in the intervention group in physical (p <0.001) and psychological (p <0.001) subscales.

Conclusion: The results of the current study support the effectiveness of telenursing in improving the quality of life of caregivers of older stroke patients.

背景:中风患者的家庭护理人员承受着沉重的护理负担,影响着他们的生活质量。远程护理能以最低的成本为护理者和患者提供全面的服务。因此,本研究旨在调查远程护理对老年中风患者护理者生活质量的影响:方法:共有 79 位老年中风患者的家庭护理者参与了这项随机临床试验。样本选自伊朗加兹温市一家教学医院收治的老年中风患者的护理人员。他们被随机分为两组。干预组通过电话随访和社交媒体参与为期 12 周的教育干预。数据收集采用巴特尔量表和 36 项简表调查(SF-36)。数据分析采用卡方检验、独立检验和配对 t 检验:参与研究的 79 名护理人员的平均年龄为 46.16 ± 11.32 岁。两组基线数据无明显差异。然而,独立 tt 检验显示心理分量表存在显著差异(p 结论:本研究结果支持了对护理人员的心理健康教育:本研究结果支持远程护理在改善老年中风患者护理者生活质量方面的有效性。
{"title":"Effect of Telenursing on the Quality of Life of Caregivers of Older Patients with Stroke.","authors":"Fatemeh Mohammadi, Hoda Bani Ardalan, Leila Dehghankar, Seyedeh Ameneh Motalebi","doi":"10.2174/1574887118666230522163725","DOIUrl":"10.2174/1574887118666230522163725","url":null,"abstract":"<p><strong>Background: </strong>Family caregivers of stroke patients suffer from a high caregiving burden that affects their quality of life. Telenursing can provide caregivers and patients with services at the lowest cost and full access. Therefore, the aim of this study was to investigate the impact of telenursing on the quality of life of caregivers of older stroke patients.</p><p><strong>Methods: </strong>A total of 79 family caregivers of older stroke patients participated in this randomized clinical trial. The samples were selected from caregivers of older stroke patients admitted to a teaching hospital in Qazvin, Iran. They were randomly divided into two groups. The intervention group participated in an educational intervention for 12 weeks through telephone follow-up and social media. The Barthel Scale and the 36-item Short Form Survey (SF-36) were used for data collection. The chi-square and independent and paired t-tests were used to analyze the data.</p><p><strong>Results: </strong>The mean age of 79 caregivers participating in the study was 46.16 ± 11.32 years. No significant differences were found between the two groups at baseline. However, the independent ttest showed significant differences in the psychological subscale (p <0.001) between the intervention and control groups after the intervention. In addition, the results of the paired t-test showed significant improvements in the intervention group in physical (p <0.001) and psychological (p <0.001) subscales.</p><p><strong>Conclusion: </strong>The results of the current study support the effectiveness of telenursing in improving the quality of life of caregivers of older stroke patients.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"275-281"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9512307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SARS-CoV-2 Detection and COVID-19 Diagnosis: A Bird's Eye View. SARS-CoV-2检测和COVID-19诊断:鸟瞰
IF 1.9 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887118666230413092826
Abdullah R Alzahrani, Qaiser Jabeen, Imran Shahid, Saeed S Al-Ghamdi, Naiyer Shahzad, Sidra Rehman, Alanood S Algarni, Ghazi A Bamagous, Ibrahim Mufadhi M AlanazI, Ibrahim Abdel Aziz Ibrahim

The battle against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) associated coronavirus disease 2019 (COVID-19) is continued worldwide by administering firsttime emergency authorized novel mRNA-based and conventional vector-antigen-based anti- COVID-19 vaccines to prevent further transmission of the virus as well as to reduce the severe respiratory complications of the infection in infected individuals. However; the emergence of numerous SARS-CoV-2 variants is of concern, and the identification of certain breakthrough and reinfection cases in vaccinated individuals as well as new cases soaring in some low-to-middle income countries (LMICs) and even in some resource-replete nations have raised concerns that only vaccine jabs would not be sufficient to control and vanquishing the pandemic. Lack of screening for asymptomatic COVID-19-infected subjects and inefficient management of diagnosed COVID-19 infections also pose some concerns and the need to fill the gaps among policies and strategies to reduce the pandemic in hospitals, healthcare services, and the general community. For this purpose, the development and deployment of rapid screening and diagnostic procedures are prerequisites in premises with high infection rates as well as to screen mass unaffected COVID-19 populations. Novel methods of variant identification and genome surveillance studies would be an asset to minimize virus transmission and infection severity. The proposition of this pragmatic review explores current paradigms for the screening of SARS-CoV-2 variants, identification, and diagnosis of COVID-19 infection, and insights into the late-stage development of new methods to better understand virus super spread variants and genome surveillance studies to predict pandemic trajectories.

在全球范围内,抗击2019年严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2)相关冠状病毒病(COVID-19)的斗争仍在继续,通过首次紧急授权的新型基于mrna和传统基于载体抗原的抗COVID-19疫苗,防止该病毒的进一步传播,并减少感染者感染的严重呼吸道并发症。然而;许多SARS-CoV-2变种的出现令人担忧,在接种疫苗的个人中发现了某些突破和再感染病例,以及一些中低收入国家甚至一些资源丰富的国家的新病例激增,令人担心仅接种疫苗不足以控制和战胜大流行。缺乏对无症状COVID-19感染者的筛查和对COVID-19确诊感染的低效管理也令人担忧,需要填补在医院、卫生保健服务机构和一般社区减少大流行的政策和战略之间的空白。为此,制定和部署快速筛查和诊断程序是在高感染率场所以及筛查大量未受影响的COVID-19人群的先决条件。变异鉴定和基因组监测研究的新方法将是最小化病毒传播和感染严重程度的资产。这篇实用的综述探讨了SARS-CoV-2变异的筛选、COVID-19感染的鉴定和诊断的当前范式,以及更好地理解病毒超级传播变异和基因组监测研究以预测大流行轨迹的新方法的后期发展的见解。
{"title":"SARS-CoV-2 Detection and COVID-19 Diagnosis: A Bird's Eye View.","authors":"Abdullah R Alzahrani,&nbsp;Qaiser Jabeen,&nbsp;Imran Shahid,&nbsp;Saeed S Al-Ghamdi,&nbsp;Naiyer Shahzad,&nbsp;Sidra Rehman,&nbsp;Alanood S Algarni,&nbsp;Ghazi A Bamagous,&nbsp;Ibrahim Mufadhi M AlanazI,&nbsp;Ibrahim Abdel Aziz Ibrahim","doi":"10.2174/1574887118666230413092826","DOIUrl":"https://doi.org/10.2174/1574887118666230413092826","url":null,"abstract":"<p><p>The battle against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) associated coronavirus disease 2019 (COVID-19) is continued worldwide by administering firsttime emergency authorized novel mRNA-based and conventional vector-antigen-based anti- COVID-19 vaccines to prevent further transmission of the virus as well as to reduce the severe respiratory complications of the infection in infected individuals. However; the emergence of numerous SARS-CoV-2 variants is of concern, and the identification of certain breakthrough and reinfection cases in vaccinated individuals as well as new cases soaring in some low-to-middle income countries (LMICs) and even in some resource-replete nations have raised concerns that only vaccine jabs would not be sufficient to control and vanquishing the pandemic. Lack of screening for asymptomatic COVID-19-infected subjects and inefficient management of diagnosed COVID-19 infections also pose some concerns and the need to fill the gaps among policies and strategies to reduce the pandemic in hospitals, healthcare services, and the general community. For this purpose, the development and deployment of rapid screening and diagnostic procedures are prerequisites in premises with high infection rates as well as to screen mass unaffected COVID-19 populations. Novel methods of variant identification and genome surveillance studies would be an asset to minimize virus transmission and infection severity. The proposition of this pragmatic review explores current paradigms for the screening of SARS-CoV-2 variants, identification, and diagnosis of COVID-19 infection, and insights into the late-stage development of new methods to better understand virus super spread variants and genome surveillance studies to predict pandemic trajectories.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":"18 3","pages":"181-205"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10556976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prospective Meta-analysis of Weight Loss Regained and Success Rate of Argon Plasma Coagulation to Suture and Surgery Procedures Post-bariatric Surgery: Status of the Art of Endoscopic Treatment. 氩等离子体凝固术对减肥手术后缝合和手术程序的体重恢复和成功率的前瞻性 Meta 分析:内窥镜治疗艺术的现状。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887118666230822110724
Idiberto José Zotarelli-Filho, Luiz Gustavo de Quadros, Manoel Galvão Neto, Samadhi W Rajapaksa, Janaki Vidanapathirana, Durval Ribas Filho, Carlos Alberto Nogueira-de-Almeida

Background: This study performed a meta-analysis to compare the safety and efficacy of argon plasma coagulation (APC) concerning suture (SUT) and surgery (SUR).

Methods: The One-Way tests were applied, with p <0.05 significant. The value of R2 was analyzed (heterogeneity), and the risk of bias of articles was evaluated.

Results: A total of 34 studies were found, eight about APC, twenty about SUT, and six about SUR. For the percentage of Weight Loss Regained (%WLR), the means for APC, SUT, and SUR were 19.39 ± 10.94, 26.06 ± 16.71, and 17.05 ± 9.85, and for success rate (%SR), the means were 89.75 ± 16.75, 86.80 ± 11.44, and 76.00 ± 21.57, respectively with p >0.05, with R2 ≥ 50%.

Conclusion: The APC proved to be efficient and safe like the other techniques.

背景:本研究通过荟萃分析比较了氩等离子体凝固术(APC)对缝合(SUT)和手术(SUR)的安全性和有效性:本研究进行了一项荟萃分析,以比较氩等离子体凝固(APC)对缝合(SUT)和手术(SUR)的安全性和有效性:方法: 采用单向检验,P 结果:共找到 34 项研究,其中 8 项关于 APC,20 项关于 SUT,6 项关于 SUR。在体重减轻恢复百分比(%WLR)方面,APC、SUT 和 SUR 的平均值分别为 19.39 ± 10.94、26.06 ± 16.71 和 17.05 ± 9.85,在成功率(%SR)方面,平均值分别为 89.75 ± 16.75、86.80 ± 11.44 和 76.00 ± 21.57,P>0.05,R2≥50%:事实证明,APC 与其他技术一样高效、安全。
{"title":"Prospective Meta-analysis of Weight Loss Regained and Success Rate of Argon Plasma Coagulation to Suture and Surgery Procedures Post-bariatric Surgery: Status of the Art of Endoscopic Treatment.","authors":"Idiberto José Zotarelli-Filho, Luiz Gustavo de Quadros, Manoel Galvão Neto, Samadhi W Rajapaksa, Janaki Vidanapathirana, Durval Ribas Filho, Carlos Alberto Nogueira-de-Almeida","doi":"10.2174/1574887118666230822110724","DOIUrl":"10.2174/1574887118666230822110724","url":null,"abstract":"<p><strong>Background: </strong>This study performed a meta-analysis to compare the safety and efficacy of argon plasma coagulation (APC) concerning suture (SUT) and surgery (SUR).</p><p><strong>Methods: </strong>The One-Way tests were applied, with p <0.05 significant. The value of R2 was analyzed (heterogeneity), and the risk of bias of articles was evaluated.</p><p><strong>Results: </strong>A total of 34 studies were found, eight about APC, twenty about SUT, and six about SUR. For the percentage of Weight Loss Regained (%WLR), the means for APC, SUT, and SUR were 19.39 ± 10.94, 26.06 ± 16.71, and 17.05 ± 9.85, and for success rate (%SR), the means were 89.75 ± 16.75, 86.80 ± 11.44, and 76.00 ± 21.57, respectively with p >0.05, with R<sup>2</sup> ≥ 50%.</p><p><strong>Conclusion: </strong>The APC proved to be efficient and safe like the other techniques.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"239-250"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10426417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment. 二甲双胍:一种有前途的放射增敏剂用于直肠癌的新辅助治疗。
IF 1.9 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/1574887118666230428114349
Nikolaos S Georgopoulos, Maria Tolia, Davide Mauri, Konstantinos Kamposioras, Nikolaos Charalampakis, Nikolaos Tsoukalas, Areti Gkantaifi

Background: Neoadjuvant chemoradiotherapy (nCRT) decreases the risk of local recurrence after surgery in patients with locally advanced rectal cancer (LARC) and metformin is constantly gaining scientific interest due to its potentially radiosensitizing effect.

Objective: This review article aims to better clarify the role of metformin as a radiosensitizer in patients with LARC undergoing neoadjuvant concurrent chemoradiotherapy.

Methods: We used the PubMed database to retrieve journal articles and the inclusion criteria were all human studies that illustrated the effective role of metformin in the neoadjuvant setting of locally advanced rectal cancer.

Results: Our search resulted in 17 citations, of which 10 eventually fulfilled the inclusion criteria of our study. Promising results (improved tumor and nodal regression as well as higher pathologic complete response rate) have been occasionally documented with metformin use in some of the included studies. However, regarding survival and all-cause mortality, no significant difference has been found.

Conclusion: Metformin might constitute a highly promising radiosensitizer in neoadjuvant LARC treatment attracting much scientific interest. Due to the lack of studies with high evidence, further advanced research is required to enhance the existing knowledge about its potential value in this field.

背景:新辅助放化疗(nCRT)降低了局部晚期直肠癌(LARC)患者术后局部复发的风险,二甲双胍因其潜在的放射增敏作用而不断受到科学的关注。目的:本文旨在更好地阐明二甲双胍作为放射增敏剂在LARC患者接受新辅助同步放化疗中的作用。方法:我们使用PubMed数据库检索期刊文章,纳入标准均为证明二甲双胍在局部晚期直肠癌新辅助治疗中的有效作用的人类研究。结果:我们检索到17条引文,其中10条最终符合我们研究的纳入标准。在一些纳入的研究中,二甲双胍的使用偶有令人鼓舞的结果(改善肿瘤和淋巴结消退以及更高的病理完全缓解率)。然而,关于生存率和全因死亡率,没有发现显著差异。结论:二甲双胍可能是一种非常有前途的放射增敏剂,在LARC的新辅助治疗中引起了广泛的科学关注。由于缺乏高证据的研究,需要进一步深入研究以增强其在该领域潜在价值的现有知识。
{"title":"Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment.","authors":"Nikolaos S Georgopoulos,&nbsp;Maria Tolia,&nbsp;Davide Mauri,&nbsp;Konstantinos Kamposioras,&nbsp;Nikolaos Charalampakis,&nbsp;Nikolaos Tsoukalas,&nbsp;Areti Gkantaifi","doi":"10.2174/1574887118666230428114349","DOIUrl":"https://doi.org/10.2174/1574887118666230428114349","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemoradiotherapy (nCRT) decreases the risk of local recurrence after surgery in patients with locally advanced rectal cancer (LARC) and metformin is constantly gaining scientific interest due to its potentially radiosensitizing effect.</p><p><strong>Objective: </strong>This review article aims to better clarify the role of metformin as a radiosensitizer in patients with LARC undergoing neoadjuvant concurrent chemoradiotherapy.</p><p><strong>Methods: </strong>We used the PubMed database to retrieve journal articles and the inclusion criteria were all human studies that illustrated the effective role of metformin in the neoadjuvant setting of locally advanced rectal cancer.</p><p><strong>Results: </strong>Our search resulted in 17 citations, of which 10 eventually fulfilled the inclusion criteria of our study. Promising results (improved tumor and nodal regression as well as higher pathologic complete response rate) have been occasionally documented with metformin use in some of the included studies. However, regarding survival and all-cause mortality, no significant difference has been found.</p><p><strong>Conclusion: </strong>Metformin might constitute a highly promising radiosensitizer in neoadjuvant LARC treatment attracting much scientific interest. Due to the lack of studies with high evidence, further advanced research is required to enhance the existing knowledge about its potential value in this field.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":"18 3","pages":"172-180"},"PeriodicalIF":1.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10207085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the Relationship between the Attitude Towards Infertility and Stress Coping Strategies among Couples undergoing Assisted Reproduction Treatment. 研究接受辅助生殖治疗的夫妇对不孕不育的态度与压力应对策略之间的关系。
IF 1.4 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2023-01-01 DOI: 10.2174/0115748871262224230919092032
Fatemeh Anjom Rouz, Mona Rahnavardi, Vahideh Hafezi, Fatemeh Rafat, Ehsan Kazemnezhad Leili, Arezoo Shayan, Zahra Karami

Introduction: Infertility and its treatment methods among couples have psychological and social consequences. To encounter these consequences, coping strategies are commonly used, which are influenced by various factors, such as the attitude of couples toward infertility.

Objective: This study aims to determine the relationship between attitudes toward infertility and stress-coping strategies among couples undergoing Assisted Reproduction Treatment, referring to the infertility clinic of Al-Zahra Educational Center.

Methods: This study was a cross-sectional study performed on 153 couples referred to Al-Zahra Infertility Clinic in Rasht. Three instruments (demographic questionnaire, attitude, and Lazarus coping strategies questionnaire) were used with regard to the inclusion restrictions.

Results: Between the two variables of individual and social information factors and the attitude of couples toward infertility, only the duration of infertility factor revealed a significant relationship (p <0.05); and in explaining the relationship between individual and social variables and coping strategies, the lack of insurance in both genders with an emotion-oriented strategy, the female infertility factor in women with the confrontational adjustment domain, and treatment in a discontinuous way in both genders have a significant relationship with the problem-oriented domain (p <0.05). Accountability and problem-solving strategies in women and an escapeavoidance strategy in infertile men have been identified as the most important predictors of attitude toward infertility.

Conclusion: There is a relationship between attitudes toward infertility and coping strategies. However, the impact of community culture on the type of coping strategies used in this study has led to different results in some cases from other studies.

引言:夫妇不孕不育及其治疗方法会产生心理和社会后果。为了应对这些后果,通常会使用应对策略,这些策略受到各种因素的影响,例如夫妇对不孕不育的态度。目的:本研究旨在确定接受辅助生殖治疗的夫妇对不孕不育的态度与压力应对策略之间的关系,参考Al Zahra教育中心的不孕不育诊所。关于包容限制,使用了三种工具(人口统计问卷、态度和拉撒路应对策略问卷)。结果:在个体和社会信息因素以及夫妇对不孕不育的态度两个变量之间,只有不孕因素的持续时间显示出显著的关系(p结论:对不孕的态度与应对策略之间存在关系。然而,社区文化对本研究中使用的应对策略类型的影响导致在某些情况下与其他研究不同的结果。
{"title":"Investigating the Relationship between the Attitude Towards Infertility and Stress Coping Strategies among Couples undergoing Assisted Reproduction Treatment.","authors":"Fatemeh Anjom Rouz, Mona Rahnavardi, Vahideh Hafezi, Fatemeh Rafat, Ehsan Kazemnezhad Leili, Arezoo Shayan, Zahra Karami","doi":"10.2174/0115748871262224230919092032","DOIUrl":"10.2174/0115748871262224230919092032","url":null,"abstract":"<p><strong>Introduction: </strong>Infertility and its treatment methods among couples have psychological and social consequences. To encounter these consequences, coping strategies are commonly used, which are influenced by various factors, such as the attitude of couples toward infertility.</p><p><strong>Objective: </strong>This study aims to determine the relationship between attitudes toward infertility and stress-coping strategies among couples undergoing Assisted Reproduction Treatment, referring to the infertility clinic of Al-Zahra Educational Center.</p><p><strong>Methods: </strong>This study was a cross-sectional study performed on 153 couples referred to Al-Zahra Infertility Clinic in Rasht. Three instruments (demographic questionnaire, attitude, and Lazarus coping strategies questionnaire) were used with regard to the inclusion restrictions.</p><p><strong>Results: </strong>Between the two variables of individual and social information factors and the attitude of couples toward infertility, only the duration of infertility factor revealed a significant relationship (p <0.05); and in explaining the relationship between individual and social variables and coping strategies, the lack of insurance in both genders with an emotion-oriented strategy, the female infertility factor in women with the confrontational adjustment domain, and treatment in a discontinuous way in both genders have a significant relationship with the problem-oriented domain (p <0.05). Accountability and problem-solving strategies in women and an escapeavoidance strategy in infertile men have been identified as the most important predictors of attitude toward infertility.</p><p><strong>Conclusion: </strong>There is a relationship between attitudes toward infertility and coping strategies. However, the impact of community culture on the type of coping strategies used in this study has led to different results in some cases from other studies.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"251-257"},"PeriodicalIF":1.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41149878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reviews on recent clinical trials
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1